“onepharm was founded jointly by the management and Avir Green Hills Biotechnology in 2005. onepharm is a Vienna-based innovative pharmaceutical company with a focus on the development of dental drugs for the treatment of periodontal disease based on its lead candidate OPM-3023. BfArM approved a clinical phase 2 trial in 2009, the start of the study is planned for 2010. Furthermore, a new microsphere based formulation developemnt has been started to deliver OPM-3023 locally.
With a international advisory board of dental top experts onepharm is well positioned to successfully transfer its lead candidates into successful products.”
